Study on SMYD3 and metabolism in colorectal cancer that spread to liver
Part of Cancer, Digestive system clinical trials.
This trial looks at how a protein called SMYD3 affects energy use in colorectal cancer cells that have spread to the liver. It may help doctors understand why some cancers grow faster and find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are having surgery to remove colorectal cancer and/or liver metastases from colorectal cancer.
- You have leftover tumor tissue from surgery that isn't needed for diagnosis.
- You sign a consent form allowing researchers to use your tissue samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different blood tests to find the best way to detect tiny bits of cancer DNA after surgery for stage III colorectal cancer. It aims to help doctors decide if additional chemotherapy is needed to prevent the cancer from coming back.
This trial is studying patients with colorectal cancer who are scheduled for surgery. Researchers want to learn more about the cancer to improve future treatments.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This study looks for biological markers that can help predict where colorectal cancer might spread. It aims to find patterns that could guide future treatment decisions. By understanding these markers, doctors may be able to detect and manage cancer recurrence earlier.
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
This study focuses on people with colon cancer (CRC) that has spread to the liver. It looks at factors that may affect liver metastases and could help doctors better understand who may benefit from future treatments.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.